Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Anastrozole | Testosterone Propionate | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 0.25-0.5 mg twice weekly as a TRT adjunct for estrogen management. Stand-alone hypogonadism: 1 mg twice weekly. | Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection. |
| Timing | Take on testosterone injection days or the day after when aromatization peaks. Consistent schedule for stable estradiol control. | Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation. |
| Cycle Duration | Ongoing as needed alongside TRT. Reassess every 3-6 months with estradiol labs. Goal is minimal effective dose. | Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden. |
| Evidence Level | strong_human | strong_human |
Anastrozole is a potent, selective, non-steroidal third-generation aromatase inhibitor that competitively binds the heme group of cytochrome P450 aromatase (CYP19A1), blocking the conversion of testosterone to estradiol and androstenedione to estrone. In men on TRT, this reduces circulating estradiol by 50-80%, shifting the testosterone-to-estradiol ratio favorably. Estrogen suppression releases hypothalamic negative feedback, increasing GnRH, LH, and FSH secretion in non-TRT contexts. Complete estrogen ablation is detrimental to bone density, lipid metabolism, and cognitive function.
Research indicates 0.25-0.5 mg twice weekly as a TRT adjunct for estrogen management. Stand-alone hypogonadism: 1 mg twice weekly.
Take on testosterone injection days or the day after when aromatization peaks. Consistent schedule for stable estradiol control.
Ongoing as needed alongside TRT. Reassess every 3-6 months with estradiol labs. Goal is minimal effective dose.
Testosterone propionate is a short-acting esterified testosterone with a propionic acid ester, resulting in a half-life of approximately 0.8-1.5 days. Rapid hydrolysis by serum esterases produces a sharp testosterone spike followed by quick clearance. It activates the same androgen receptor-mediated genomic and non-genomic pathways as longer esters, but the pharmacokinetic profile demands frequent dosing. The short duration makes it useful for rapid onset situations and fine-tuned dose titration.
Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection.
Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation.
Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →